搜索
 > 【FKBP12】重组蛋白信息

FKBP12信息

英文名称:FK506-binding protein 1A
中文名称:FK506结合蛋白-1A
靶点别称:FKBP12,12 kDa FKBP,FKBP-1A,FKBP1 ,FKBP1A,PPIase FKBP1A,Immunophilin FKBP12,Peptidyl-prolyl cis-trans isomerase FKBP1A,FKBP-12,Calstabin-1,FK506-binding protein 1A,Rotamase,12 kDa FK506-binding protein
上市药物数量:1
临床药物数量:1
最高研发阶段:批准上市

FKBP12产品列表

产品库
物种
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
FKA-H5122
Human
Human FKBP12 / FKBP1A Protein, His Tag
 
评论(0)
 

FKBP12 分子别名

FKBP1A,FKBP1,Calstabin-1,FKBP12,Rotamase,PKC12,PPIASE

FKBP12 分子背景

Peptidyl-prolyl cis-trans isomerase FKBP1A, a member of the FKBP-type PPIase family and FKBP1 subfamily, is also known as FK506-binding protein 1A, immunophilin FKBP12 and 12 kDa FK506-binding protein, which contains one PPIase FKBP-type domain. FKBP1A is a cis-trans prolyl isomerase that binds the immunosuppressants FK506 (tacrolimus) and rapamycin (sirolimus).FKBP1A interacts with several intracellular signal transduction proteins including type I TGF-beta receptor. FKBP1A can also interact with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine receptor. Furthermore, FKBP1A can recruite SMAD7 to ACVR1B which prevents the association of SMAD2 and SMAD3 with the activin receptor complex, thereby blocking the activin signal.

FKBP12 参考文献

FKBP12上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Tacrolimus Hydrate 他克莫司水合物 FK-506; FK-506E; FK-506MR; FR-900506; L-679934; MR-4; RTU-007; LCP-Tacro 批准上市 安斯泰来 PROGRAF fda ASTELLAS 1994-04-08 溃疡性结肠炎, 肌无力, 红斑狼疮性肾炎, 移植排斥反应, 特应性皮炎, 冠状动脉再狭窄, 类风湿性关节炎, 过敏性结膜炎 详情

FKBP12临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Rimiducid AP-1903,AP1903 临床二期 Ariad, Bellicum 骨髓增生异常综合征, 急性骨髓性白血病, 急性淋巴细胞白血病, 非霍奇金淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定